MedTrace Logo

Brain Oligometastasis in NSCLC

NCT07389642 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2026-02-05

No results posted yet for this study

Summary

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute

Conditions

Interventions

OTHER

Standard treatments / multiple strategies

Standard treatments / multiple strategies

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07389642 on ClinicalTrials.gov